IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A process for producing solid dosage forms, in which a moldable composition which comprises

a) 50 to 99.4% by weight of at least one crosslinked nonthermoplastic carrier,

b) 0.5 to 30% by weight of at least one adjuvant selected from the group consisting of thermoplastic polymers, lipids, sugar alcohols, sugar alcohol derivatives and solubilizers and

c) 0.1 to 49.5% by weight of at least one active ingredient,

is formed at a temperature at or above the softening point of the adjuvant, but at least 70°C, and subsequently cooled.

Claim 2 (Original): The process according to claim 1, where the composition comprises

a) 50 to 90% by weight of at least one crosslinked nonthermoplastic carrier,

b1) 5 to 30% by weight of at least one thermoplastic polymer,

b2) 0.5 to 20% by weight of at least one solubilizer,

c) 0.1 to 45.5% by weight of at least one active ingredient.

Claim 3 (Currently Amended): The process according to claim 1 ~~or 2~~, where the crosslinked nonthermoplastic carrier is selected from the group consisting of crosslinked polyvinylpyrrolidone, ~~and~~ crosslinked sodium carboxymethylcellulose and mixtures thereof.

Claim 4 (Currently Amended): The process according to ~~any of the preceding claims~~ claim 1, where the thermoplastic polymer is a homo- or copolymer of vinylpyrrolidone.

Claim 5 (Currently Amended): The process according to ~~any of the preceding claims~~ claim 1, where the sugar alcohol is selected from the group consisting of sorbitol, xylitol, mannitol, maltitol, ~~and~~ the sugar alcohol derivative isomalt and mixtures thereof.

Claim 6 (Currently Amended): The process according to ~~any of the preceding claims~~ claim 1, where the lipid is selected from the group consisting of fatty acids, fatty alcohols, fats, waxes, mono- and diglycerides, ~~and~~ phosphatides and mixtures thereof.

Claim 7 (Currently Amended): The process according to ~~any of the preceding claims~~ claim 1, where the solubilizer is selected from the group consisting of sorbitan fatty acid esters, polyalkoxylated fatty acid esters, ~~and~~ polyalkoxylated ethers of fatty alcohols and mixtures thereof.

Claim 8 (Currently Amended): The process according to ~~any of the preceding claims~~ claim 1, where the active ingredient has a solubility in water at 25°C of less than 1 mg/ml.

Claim 9 (Currently Amended): The process according to ~~any of the preceding claims~~ claim 1, where the cooled composition is comminuted and compressed to the dosage form.